Overview |
bs-5504R-PE-Cy5.5 |
MAPKAPK5(Thr182) Polyclonal Antibody, PE-Cy5.5 Conjugated |
WB |
This phosphorylation site is homologous to that of Thr182 in Mouse. |
Rat |
Human, Mouse, Dog, Cow, Pig, Horse, Chicken, Rabbit |
Specifications |
PE-Cy5.5 |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human MAPKAPK5 around the phosphorylation site of Thr182 |
Thr182 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
8550 |
Q8IW41 |
Cytoplasm, Nucleus |
MK5; MK-5; PRAK; MAPKAP-K5; MAP kinase-activated protein kinase 5; MAPK-activated protein kinase 5; MAPKAP kinase 5; MAPKAPK-5; p38-regulated/activated protein kinase; MAPKAPK5 |
Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34C, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement. |
Application Dilution |
WB |
1:300-5000 |